Nasdaq-listed Lifeward said on August 5, 2026 that it has launched a six-month pilot with Ottobock Care to make the ReWalk 7 personal exoskeleton available through one of the largest U.S. orthotics-and-prosthetics patient care networks. The agreement is designed as a capital-efficient channel-partner model that could seed a broader national rollout of powered mobility technology.
What the pilot covers
Ottobock Care operates more than 50 patient-care clinics in the United States, staffed by certified prosthetist-orthotists, clinical liaisons and technical specialists. During the pilot the two companies will train clinical teams, build regional reimbursement expertise and increase awareness of ReWalk 7 across rehabilitation hospitals and spinal cord injury centres. Lifeward chief executive Mark Grant described the deal as a critical piece of the company's strategy to reach more patients through experienced patient-care organisations.
Neurorehabilitation goes mainstream
ReWalk 7 is the latest generation of the ReWalk personal exoskeleton, an FDA-cleared powered wearable device that restores upright ambulation for people with spinal cord injury. Lifeward's wider neurorehabilitation portfolio includes the AlterG anti-gravity treadmill, ReStore soft exo-suit and MyoCycle functional electrical stimulation cycle. The channel partnership complements a growing set of clinical collaborations, including Lifeward's earlier work with the Shirley Ryan AbilityLab.
Why it matters for the sector
Access, reimbursement and clinical training remain the biggest barriers to at-home use of powered exoskeletons. Anchoring distribution inside an established prosthetics-and-orthotics network gives Lifeward reach without adding clinic infrastructure of its own, while Ottobock deepens a bet on neural rehabilitation that already included its 2026 lead of Phantom Neuro's $19M Series A. Analysts covering the space have flagged similar partnership models as a template for other neurotech vendors trying to move from pilot deployments to reimbursed standard-of-care equipment.
Reporting based on coverage from GlobeNewswire, Yahoo Finance and StockTitan.